<DOC>
	<DOCNO>NCT01075178</DOCNO>
	<brief_summary>Retrospective medical record review study specific adverse event child congenital heart disease receive palivizumab prophylaxis serious respiratory syncytial virus infection control subject receive palivizumab</brief_summary>
	<brief_title>Retrospective Palivizumab Study Children With Hemodynamically Significant Congenital Heart Disease</brief_title>
	<detailed_description>This observational , non-interventional , retrospective cohort study infant hemodynamically significant congenital heart disease ( HSCHD ) less 24 month age first dose palivizumab administer ( CASES ) , infant diagnose hemodynamically significant congenital heart disease receive palivizumab historical respiratory syncytial virus ( RSV ) season first 24 month life ( CONTROLS ) . CASES match CONTROLS base RSV season , age , type cardiac lesion , type prior corrective cardiac surgery . Subject medical record review occurrence clinical end point infection , arrhythmia , and/or death meet criterion serious adverse event . The group compare number percent subject experience primary serious adverse event ( individually collectively ) define 8-month chart review period .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>1 . Subject must document hemodynamically significant congenital heart disease ( Note : Children uncomplicated small atrial ventricular septal defect patent ductus arteriosus eligible ) . 2 . Subject must unoperated partially correct congenital heart disease . 3 . Subject must receive least one dose palivizumab prophylaxis Respiratory Syncytial Virus season September 1 April 30 ( CASES ) , would consider eligible palivizumab prophylaxis ( CONTROLS ) . 4 . Subject must &lt; 24 month age time first dose palivizumab prophylaxis ( CASES ) &lt; 32 month age end assign Respiratory Syncytial Virus season would eligible receive palivizumab drug approve European Union ( CONTROLS ) . 5 . Subject 's parent , guardian , legal representative voluntarily sign dated Release Information Form allow review medical record collection pertinent study data . 1 . Subject contraindicate treatment palivizumab accord current European product label . 2 . Subject full correction Congenital Heart Disease . 3 . Subject receive palivizumab approval use Congenital Heart Disease ( CASES ) , subject receive palivizumab time ( CONTROLS ) . 4 . Subject already include study prior Respiratory Syncytial Virus season .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Infection</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Death</keyword>
	<keyword>Palivizumab</keyword>
	<keyword>Safety</keyword>
	<keyword>Hemodynamically Significant Congenital Heart Disease</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Observational</keyword>
</DOC>